Search
Hydroxyurea
go.drugbank.com/drugs/DB01005ApprovedInvestigational[A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. … Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928.
Temazepam
go.drugbank.com/drugs/DB00231ApprovedIn particular, before temazepam saw regular prescription use in civilians it was - and still is - employed by the US military as a sedative-hypnotic medication to be taken by soldiers, pilots, etc. to … capable of developing drug tolerance, physical dependence, and addiction in users.
Oseltamivir
go.drugbank.com/drugs/DB00198ApprovedInvestigationalgenerally no benefit in use beyond 48 hours for healthy, low-risk individuals as influenza is a self-limiting illness. … The clinical benefit of use of oseltamivir is greatest when administered within 48 hours of the onset of influenza symptoms since effectiveness decreases significantly after that point in time; there is
Products: OSELMIR 12 MG/ML ORAL SÜSPANSİYON HAZIRLAMAK İÇİN TOZ, 65 ML, Cyovel 6 mg/ml Oral Süspansiyon Hazırlamak İçin Toz, 65 MLPirbuterol
go.drugbank.com/drugs/DB01291ApprovedWithdrawnWhile it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing … in a concentration between 10-50%.
Categories: Compounds used in a research, industrial, or household settingSparfloxacin
go.drugbank.com/drugs/DB01208ApprovedWithdrawnDNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. … Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase.
Categories: Topoisomerase II InhibitorsSaquinavir
go.drugbank.com/drugs/DB01232ApprovedInvestigationalIn 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared … Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection.
Malic acid
go.drugbank.com/drugs/DB12751InvestigationalMalic acid has been used in trials studying the treatment of Xerostomia, Depression, and Hypertension.
Mixtures: AKE 1100 GLUKOZLU IV SOLOSYONU, 500 ML, AKE 1100 GLUKOZLU IV SOLOSYONU, 1000 MLInebilizumab
go.drugbank.com/drugs/DB12530ApprovedInvestigationalInebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients suffering from NMOSD. … [L49861] In April 2025, inebilizumab was additionally approved by the FDA for immunoglobulin G4-related disease (IgG4-RD).[L52705,L14315] It is the first and only FDA-approved treatment for IgG4-RD.
Zapomeran
go.drugbank.com/drugs/DB21761Approved[L52585,L52590] Previously marketed in Japan, in December 2024 Kostaive became the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission.[L52580,L52585] … Zapomeran, marketed under the brand name Kostaive (ARCT-154), is a self-amplifying mRNA COVID-19 vaccine for individuals 18 years and older.
Bismuth subgallate
go.drugbank.com/drugs/DB13909ApprovedIt is a heavy metal salt of gallic acid that is highly insoluble and poorly absorbed. … internal deodorant where it is often employed as the primary active ingredient.